Skip to main navigation Skip to search Skip to main content

Adjuvants and antigen-delivery systems for subunit vaccines against tuberculosis

Research output: Contribution to journal › Editorial

8 Scopus citations

Abstract

The only licensed vaccine against tuberculosis is BCG. However, BCG has failed to provide consistent protection against tuberculosis, especially pulmonary disease in adults. Furthermore, the use of BCG is contraindicated in immunocompromised subjects. The research towards the development of new vaccines against TB includes the use of Mycobacterium tuberculosis antigens as subunit vaccines. Such vaccines may be used either alone or in the prime-boost model in BCG-vaccinated people. However, the antigens for subunit vaccines require adjuvants and/or delivery systems to induce appropriate and protective immune responses against tuberculosis and other diseases. Articles published in this Special Issue have studied the pathogenesis of BCG in children and the use of BCG and recombinant BCG as potential vaccines against asthma. Furthermore, the use of different adjuvants and delivery systems in inducing the protective immune responses after immunization with subunit vaccines has been described.

Original languageEnglish
Article number972
JournalVaccines
Volume9
Issue number9
DOIs
StatePublished - Sep 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Adjuvants
  • Antigens
  • Delivery systems
  • Subunit vaccines
  • Tuberculosis

Fingerprint

Dive into the research topics of 'Adjuvants and antigen-delivery systems for subunit vaccines against tuberculosis'. Together they form a unique fingerprint.

Cite this